Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

HIF-transcribed p53 chaperones HIF-1α.

Madan E, Parker TM, Pelham CJ, Palma AM, Peixoto ML, Nagane M, Chandaria A, Tomás AR, Canas-Marques R, Henriques V, Galzerano A, Cabral-Teixeira J, Selvendiran K, Kuppusamy P, Carvalho C, Beltran A, Moreno E, Pati UK, Gogna R.

Nucleic Acids Res. 2019 Sep 20. pii: gkz766. doi: 10.1093/nar/gkz766. [Epub ahead of print]

PMID:
31538203
2.

A Microfluidic Chip Enables Isolation of Exosomes and Establishment of Their Protein Profiles and Associated Signaling Pathways in Ovarian Cancer.

Dorayappan KDP, Gardner ML, Hisey CL, Zingarelli RA, Smith BQ, Lightfoot MDS, Gogna R, Flannery MM, Hays J, Hansford DJ, Freitas MA, Yu L, Cohn DE, Selvendiran K.

Cancer Res. 2019 Jul 1;79(13):3503-3513. doi: 10.1158/0008-5472.CAN-18-3538. Epub 2019 May 16.

PMID:
31097475
3.

Inhibition of miR-328-3p Impairs Cancer Stem Cell Function and Prevents Metastasis in Ovarian Cancer.

Srivastava AK, Banerjee A, Cui T, Han C, Cai S, Liu L, Wu D, Cui R, Li Z, Zhang X, Xie G, Selvendiran K, Patnaik S, Karpf AR, Liu J, Cohn DE, Wang QE.

Cancer Res. 2019 May 1;79(9):2314-2326. doi: 10.1158/0008-5472.CAN-18-3668. Epub 2019 Mar 20.

4.

Microfluidic affinity separation chip for selective capture and release of label-free ovarian cancer exosomes.

Hisey CL, Dorayappan KDP, Cohn DE, Selvendiran K, Hansford DJ.

Lab Chip. 2018 Oct 9;18(20):3144-3153. doi: 10.1039/c8lc00834e.

PMID:
30191215
5.

Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3/Rab proteins.

Dorayappan KDP, Wanner R, Wallbillich JJ, Saini U, Zingarelli R, Suarez AA, Cohn DE, Selvendiran K.

Oncogene. 2018 Jul;37(28):3806-3821. doi: 10.1038/s41388-018-0189-0. Epub 2018 Apr 11.

6.

The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53.

Madan E, Parker TM, Bauer MR, Dhiman A, Pelham CJ, Nagane M, Kuppusamy ML, Holmes M, Holmes TR, Shaik K, Shee K, Kiparoidze S, Smith SD, Park YA, Gomm JJ, Jones LJ, Tomás AR, Cunha AC, Selvendiran K, Hansen LA, Fersht AR, Hideg K, Gogna R, Kuppusamy P.

J Biol Chem. 2018 Mar 23;293(12):4262-4276. doi: 10.1074/jbc.RA117.000950. Epub 2018 Jan 30.

7.

STAT3/PIAS3 Levels Serve as "Early Signature" Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube.

Saini U, Suarez AA, Naidu S, Wallbillich JJ, Bixel K, Wanner RA, Bice J, Kladney RD, Lester J, Karlan BY, Goodfellow PJ, Cohn DE, Selvendiran K.

Cancer Res. 2018 Apr 1;78(7):1739-1750. doi: 10.1158/0008-5472.CAN-17-1671. Epub 2018 Jan 16.

8.

MAX Mutations in Endometrial Cancer: Clinicopathologic Associations and Recurrent MAX p.His28Arg Functional Characterization.

Walker CJ, Rush CM, Dama P, O'Hern MJ, Cosgrove CM, Gillespie JL, Zingarelli RA, Smith B, Stein ME, Mutch DG, Shakya R, Chang CW, Selvendiran K, Song JW, Cohn DE, Goodfellow PJ.

J Natl Cancer Inst. 2018 May 1;110(5):517-526. doi: 10.1093/jnci/djx238.

9.

Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma.

Bixel K, Saini U, Kumar Bid H, Fowler J, Riley M, Wanner R, Deepa Priya Dorayappan K, Rajendran S, Konishi I, Matsumura N, Cohn DE, Selvendiran K.

Int J Cancer. 2017 Nov 1;141(9):1856-1866. doi: 10.1002/ijc.30847. Epub 2017 Jul 24.

10.

High Glucose-Mediated STAT3 Activation in Endometrial Cancer Is Inhibited by Metformin: Therapeutic Implications for Endometrial Cancer.

Wallbillich JJ, Josyula S, Saini U, Zingarelli RA, Dorayappan KD, Riley MK, Wanner RA, Cohn DE, Selvendiran K.

PLoS One. 2017 Jan 23;12(1):e0170318. doi: 10.1371/journal.pone.0170318. eCollection 2017.

11.

HDAC10 as a potential therapeutic target in ovarian cancer.

Islam MM, Banerjee T, Packard CZ, Kotian S, Selvendiran K, Cohn DE, Parvin JD.

Gynecol Oncol. 2017 Mar;144(3):613-620. doi: 10.1016/j.ygyno.2017.01.009. Epub 2017 Jan 7.

12.

Autophagy Induction Results in Enhanced Anoikis Resistance in Models of Peritoneal Disease.

Chen JL, David J, Cook-Spaeth D, Casey S, Cohen D, Selvendiran K, Bekaii-Saab T, Hays JL.

Mol Cancer Res. 2017 Jan;15(1):26-34. doi: 10.1158/1541-7786.MCR-16-0200-T. Epub 2016 Nov 2.

13.

Anticancer potential of diarylidenyl piperidone derivatives, HO-4200 and H-4318, in cisplatin resistant primary ovarian cancer.

ElNaggar AC, Saini U, Naidu S, Wanner R, Sudhakar M, Fowler J, Nagane M, Kuppusamy P, Cohn DE, Selvendiran K.

Cancer Biol Ther. 2016 Oct 2;17(10):1107-1115.

14.

Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target.

Saini U, Naidu S, ElNaggar AC, Bid HK, Wallbillich JJ, Bixel K, Bolyard C, Suarez AA, Kaur B, Kuppusamy P, Hays J, Goodfellow PJ, Cohn DE, Selvendiran K.

Oncogene. 2017 Jan 12;36(2):168-181. doi: 10.1038/onc.2016.197. Epub 2016 Jun 13.

15.

The biological significance and clinical applications of exosomes in ovarian cancer.

Dorayappan KDP, Wallbillich JJ, Cohn DE, Selvendiran K.

Gynecol Oncol. 2016 Jul;142(1):199-205. doi: 10.1016/j.ygyno.2016.03.036. Epub 2016 Apr 10. Review.

16.

Targeting constitutively-activated STAT3 in hypoxic ovarian cancer, using a novel STAT3 inhibitor.

McCann GA, Naidu S, Rath KS, Bid HK, Tierney BJ, Suarez A, Varadharaj S, Zhang J, Hideg K, Houghton P, Kuppusamy P, Cohn DE, Selvendiran K.

Oncoscience. 2014 Mar 31;1(3):216-28. eCollection 2014.

17.

Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer.

Bolyard C, Yoo JY, Wang PY, Saini U, Rath KS, Cripe TP, Zhang J, Selvendiran K, Kaur B.

Clin Cancer Res. 2014 Dec 15;20(24):6479-94. doi: 10.1158/1078-0432.CCR-14-0463. Epub 2014 Oct 7.

18.

Aberrantly activated pSTAT3-Ser727 in human endometrial cancer is suppressed by HO-3867, a novel STAT3 inhibitor.

Tierney BJ, McCann GA, Naidu S, Rath KS, Saini U, Wanner R, Kuppusamy P, Suarez A, Goodfellow PJ, Cohn DE, Selvendiran K.

Gynecol Oncol. 2014 Oct;135(1):133-41. doi: 10.1016/j.ygyno.2014.07.087. Epub 2014 Jul 16.

19.

Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.

Yoo JY, Hurwitz BS, Bolyard C, Yu JG, Zhang J, Selvendiran K, Rath KS, He S, Bailey Z, Eaves D, Cripe TP, Parris DS, Caligiuri MA, Yu J, Old M, Kaur B.

Clin Cancer Res. 2014 Jul 15;20(14):3787-98. doi: 10.1158/1078-0432.CCR-14-0553. Epub 2014 May 9.

20.

HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer.

Rath KS, Naidu SK, Lata P, Bid HK, Rivera BK, McCann GA, Tierney BJ, Elnaggar AC, Bravo V, Leone G, Houghton P, Hideg K, Kuppusamy P, Cohn DE, Selvendiran K.

Cancer Res. 2014 Apr 15;74(8):2316-27. doi: 10.1158/0008-5472.CAN-13-2433. Epub 2014 Mar 3.

21.

DNA damage-binding complex recruits HDAC1 to repress Bcl-2 transcription in human ovarian cancer cells.

Zhao R, Han C, Eisenhauer E, Kroger J, Zhao W, Yu J, Selvendiran K, Liu X, Wani AA, Wang QE.

Mol Cancer Res. 2014 Mar;12(3):370-80. doi: 10.1158/1541-7786.MCR-13-0281. Epub 2013 Nov 18.

22.

Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogs.

Rath KS, McCann GA, Cohn DE, Rivera BK, Kuppusamy P, Selvendiran K.

J Ovarian Res. 2013 May 11;6(1):35. doi: 10.1186/1757-2215-6-35.

23.

Pulmonary hypertension secondary to left-heart failure involves peroxynitrite-induced downregulation of PTEN in the lung.

Ravi Y, Selvendiran K, Naidu SK, Meduru S, Citro LA, Bognár B, Khan M, Kálai T, Hideg K, Kuppusamy P, Sai-Sudhakar CB.

Hypertension. 2013 Mar;61(3):593-601. doi: 10.1161/HYPERTENSIONAHA.111.00514. Epub 2013 Jan 21.

24.

HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells.

Tierney BJ, McCann GA, Cohn DE, Eisenhauer E, Sudhakar M, Kuppusamy P, Hideg K, Selvendiran K.

Cancer Biol Ther. 2012 Jul;13(9):766-75. doi: 10.4161/cbt.20559.

PMID:
22801507
25.

Dysregulation of PTEN in cardiopulmonary vascular remodeling induced by pulmonary hypertension.

Ravi Y, Selvendiran K, Meduru S, Citro L, Naidu S, Khan M, Rivera BK, Sai-Sudhakar CB, Kuppusamy P.

Cell Biochem Biophys. 2013 Nov;67(2):363-72. doi: 10.1007/s12013-011-9332-z.

26.

PPARγ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells.

Koga H, Selvendiran K, Sivakumar R, Yoshida T, Torimura T, Ueno T, Sata M.

Int J Oncol. 2012 Mar;40(3):679-85. doi: 10.3892/ijo.2011.1237. Epub 2011 Oct 20.

PMID:
22020928
27.

HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.

Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Rivera BK, Kálai T, Hideg K, Kuppusamy P.

Cancer Biol Ther. 2011 Nov 1;12(9):837-45. doi: 10.4161/cbt.12.9.17713. Epub 2011 Nov 1.

PMID:
21885917
28.

Amelioration of doxorubicin-induced cardiotoxicity by an anticancer-antioxidant dual-function compound, HO-3867.

Dayton A, Selvendiran K, Meduru S, Khan M, Kuppusamy ML, Naidu S, Kálai T, Hideg K, Kuppusamy P.

J Pharmacol Exp Ther. 2011 Nov;339(2):350-7. doi: 10.1124/jpet.111.183681. Epub 2011 Jul 28.

29.

Synthesis of N-substituted 3,5-bis(arylidene)-4-piperidones with high antitumor and antioxidant activity.

Kálai T, Kuppusamy ML, Balog M, Selvendiran K, Rivera BK, Kuppusamy P, Hideg K.

J Med Chem. 2011 Aug 11;54(15):5414-21. doi: 10.1021/jm200353f. Epub 2011 Jul 6.

PMID:
21702507
30.

A modified sesamol derivative inhibits progression of atherosclerosis.

Ying Z, Kherada N, Kampfrath T, Mihai G, Simonetti O, Desikan R, Selvendiran K, Sun Q, Ziouzenkova O, Parthasarathy S, Rajagopalan S.

Arterioscler Thromb Vasc Biol. 2011 Mar;31(3):536-42. doi: 10.1161/ATVBAHA.110.219287. Epub 2010 Dec 23.

31.

Hypoxic preconditioning induces the expression of prosurvival and proangiogenic markers in mesenchymal stem cells.

Chacko SM, Ahmed S, Selvendiran K, Kuppusamy ML, Khan M, Kuppusamy P.

Am J Physiol Cell Physiol. 2010 Dec;299(6):C1562-70. doi: 10.1152/ajpcell.00221.2010. Epub 2010 Sep 22.

32.

Cellular uptake, retention and bioabsorption of HO-3867, a fluorinated curcumin analog with potential antitumor properties.

Dayton A, Selvendiran K, Kuppusamy ML, Rivera BK, Meduru S, Kálai T, Hideg K, Kuppusamy P.

Cancer Biol Ther. 2010 Nov 15;10(10):1027-32. doi: 10.4161/cbt.10.10.13250. Epub 2010 Nov 15.

33.

Crataegus oxycantha extract attenuates apoptotic incidence in myocardial ischemia-reperfusion injury by regulating Akt and HIF-1 signaling pathways.

Jayachandran KS, Khan M, Selvendiran K, Devaraj SN, Kuppusamy P.

J Cardiovasc Pharmacol. 2010 Nov;56(5):526-31. doi: 10.1097/FJC.0b013e3181f64c51.

PMID:
20729753
34.

HO-3867, a synthetic compound, inhibits the migration and invasion of ovarian carcinoma cells through downregulation of fatty acid synthase and focal adhesion kinase.

Selvendiran K, Ahmed S, Dayton A, Ravi Y, Kuppusamy ML, Bratasz A, Rivera BK, Kálai T, Hideg K, Kuppusamy P.

Mol Cancer Res. 2010 Sep;8(9):1188-97. doi: 10.1158/1541-7786.MCR-10-0201. Epub 2010 Aug 16.

35.

Oxygenation inhibits ovarian tumor growth by downregulating STAT3 and cyclin-D1 expressions.

Selvendiran K, Kuppusamy ML, Ahmed S, Bratasz A, Meenakshisundaram G, Rivera BK, Khan M, Kuppusamy P.

Cancer Biol Ther. 2010 Aug 15;10(4):386-90. Epub 2010 Aug 21.

PMID:
20562529
36.

Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts.

Selvendiran K, Tong L, Bratasz A, Kuppusamy ML, Ahmed S, Ravi Y, Trigg NJ, Rivera BK, Kálai T, Hideg K, Kuppusamy P.

Mol Cancer Ther. 2010 May;9(5):1169-79. doi: 10.1158/1535-7163.MCT-09-1207. Epub 2010 May 4.

37.

Synthesis and study of new paramagnetic and diamagnetic verapamil derivatives.

Bognár B, Ahmed S, Kuppusamy ML, Selvendiran K, Khan M, Jeko J, Hankovszky OH, Kálai T, Kuppusamy P, Hideg K.

Bioorg Med Chem. 2010 Apr 15;18(8):2954-63. doi: 10.1016/j.bmc.2010.02.040. Epub 2010 Feb 25.

38.

Cardioprotective properties of Crataegus oxycantha extract against ischemia-reperfusion injury.

Swaminathan JK, Khan M, Mohan IK, Selvendiran K, Niranjali Devaraj S, Rivera BK, Kuppusamy P.

Phytomedicine. 2010 Aug;17(10):744-52. doi: 10.1016/j.phymed.2010.01.009. Epub 2010 Feb 18.

39.

Safe and targeted anticancer efficacy of a novel class of antioxidant-conjugated difluorodiarylidenyl piperidones: differential cytotoxicity in healthy and cancer cells.

Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Tazi M, Bratasz A, Tong L, Rivera BK, Kálai T, Hideg K, Kuppusamy P.

Free Radic Biol Med. 2010 May 1;48(9):1228-35. doi: 10.1016/j.freeradbiomed.2010.02.009. Epub 2010 Feb 12.

40.

Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3.

Selvendiran K, Bratasz A, Kuppusamy ML, Tazi MF, Rivera BK, Kuppusamy P.

Int J Cancer. 2009 Nov 1;125(9):2198-204. doi: 10.1002/ijc.24601.

41.

Oxygen sensitivity and biocompatibility of an implantable paramagnetic probe for repeated measurements of tissue oxygenation.

Meenakshisundaram G, Eteshola E, Pandian RP, Bratasz A, Selvendiran K, Lee SC, Krishna MC, Swartz HM, Kuppusamy P.

Biomed Microdevices. 2009 Aug;11(4):817-26. doi: 10.1007/s10544-009-9298-4.

42.

Myocardial oxygenation and functional recovery in infarct rat hearts transplanted with mesenchymal stem cells.

Chacko SM, Khan M, Kuppusamy ML, Pandian RP, Varadharaj S, Selvendiran K, Bratasz A, Rivera BK, Kuppusamy P.

Am J Physiol Heart Circ Physiol. 2009 May;296(5):H1263-73. doi: 10.1152/ajpheart.01311.2008. Epub 2009 Mar 13.

43.

Inhibition of vascular smooth-muscle cell proliferation and arterial restenosis by HO-3867, a novel synthetic curcuminoid, through up-regulation of PTEN expression.

Selvendiran K, Kuppusamy ML, Bratasz A, Tong L, Rivera BK, Rink C, Sen CK, Kálai T, Hideg K, Kuppusamy P.

J Pharmacol Exp Ther. 2009 Jun;329(3):959-66. doi: 10.1124/jpet.108.150367. Epub 2009 Mar 10.

PMID:
19276401
44.

Autocrine loop for IGF-I receptor signaling in SLUG-mediated epithelial-mesenchymal transition.

Sivakumar R, Koga H, Selvendiran K, Maeyama M, Ueno T, Sata M.

Int J Oncol. 2009 Feb;34(2):329-38.

PMID:
19148466
45.

Cardioprotection by HO-4038, a novel verapamil derivative, targeted against ischemia and reperfusion-mediated acute myocardial infarction.

Mohan IK, Khan M, Wisel S, Selvendiran K, Sridhar A, Carnes CA, Bognar B, Kálai T, Hideg K, Kuppusamy P.

Am J Physiol Heart Circ Physiol. 2009 Jan;296(1):H140-51. doi: 10.1152/ajpheart.00687.2008. Epub 2008 Oct 31.

46.

Switching in discoid domain receptor expressions in SLUG-induced epithelial-mesenchymal transition.

Maeyama M, Koga H, Selvendiran K, Yanagimoto C, Hanada S, Taniguchi E, Kawaguchi T, Harada M, Ueno T, Sata M.

Cancer. 2008 Nov 15;113(10):2823-31. doi: 10.1002/cncr.23900.

47.

NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols.

Bratasz A, Selvendiran K, Wasowicz T, Bobko A, Khramtsov VV, Ignarro LJ, Kuppusamy P.

J Transl Med. 2008 Feb 26;6:9. doi: 10.1186/1479-5876-6-9.

48.
49.

EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression.

Selvendiran K, Tong L, Vishwanath S, Bratasz A, Trigg NJ, Kutala VK, Hideg K, Kuppusamy P.

J Biol Chem. 2007 Sep 28;282(39):28609-18. Epub 2007 Aug 7.

50.

Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK.

Weir NM, Selvendiran K, Kutala VK, Tong L, Vishwanath S, Rajaram M, Tridandapani S, Anant S, Kuppusamy P.

Cancer Biol Ther. 2007 Feb;6(2):178-84. Epub 2007 Feb 5.

Supplemental Content

Loading ...
Support Center